Bradley Miller, ESPE 2022: Advantages of somapacitan versus daily GH in children with GH deficiency
Daily growth hormone (GH) injections can be burdensome for patients and carers. Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for once-weekly administration in patients with growth hormone deficiency (GHD). In this touchENDOCRINOLOGY interview, Prof. Bradley Miller (University of Minnesota, Minneapolis, MN, USA) discusses the challenges of GH therapy in children and the advantages of somapacitan over traditional GH therapy is also discussed.Â
The abstract entitled: ‘Once-Weekly Somapacitan versus Daily GH in Children with GH Deficiency: The Randomized Phase 3 REAL 4 Trial’ was presented at the European Society for Paediatric Endocrinology, 15-17 Sept, 2022.
Questions:
- What are the challenges of growth hormone (GH) replacement therapy in children? (0:16)
- What is somapacitan and what are its advantages over traditional GH replacement therapy? (0:41)
Disclosures: Bradley Miller is a consultant for Abbvie, Ascendis Pharma, BioMarin, Bristol Myers Squibb, EMD Serono, Endo Pharmaceuticals, Novo Nordisk, Orchard Therapeutics, Pfizer, Tolmar and Vertice and discloses grant/research support from Alexion, Abbvie, Aeterna Zentaris, Amgen, Amicus, Lumos Pharma, Lysogene, Novo Nordisk, OPKO Health Pfizer, Prevail Therapeutics and Sangamo Therapeutics.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of ESPE 2022
